These results suggest that targeting METTL1 alone or in combination with immune checkpoint inhibitors holds great potential for developing effective therapeutic strategies, particularly for patients with castration-resistant prostate cancer who have limited treatment options. This evidence concerns the gene METTL1 and Familial prostate cancer.